Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
IMUC's Cash to Debt is ranked higher than
84% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. IMUC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
IMUC' s 10-Year Cash to Debt Range
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6484
N/A
No Debt
F-Score: 3
Z-Score: 3.48
M-Score: -2.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -32.24
IMUC's ROE (%) is ranked lower than
51% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. IMUC: -32.24 )
Ranked among companies with meaningful ROE (%) only.
IMUC' s 10-Year ROE (%) Range
Min: -4907.62  Med: -130.10 Max: -35.53
Current: -32.24
-4907.62
-35.53
ROA (%) -29.07
IMUC's ROA (%) is ranked lower than
52% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. IMUC: -29.07 )
Ranked among companies with meaningful ROA (%) only.
IMUC' s 10-Year ROA (%) Range
Min: -417.42  Med: -91.40 Max: -31.45
Current: -29.07
-417.42
-31.45
ROC (Joel Greenblatt) (%) -6092.26
IMUC's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. IMUC: -6092.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IMUC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -79400  Med: -18550.00 Max: -12395.77
Current: -6092.26
-79400
-12395.77
EBITDA Growth (3Y)(%) -10.60
IMUC's EBITDA Growth (3Y)(%) is ranked lower than
58% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. IMUC: -10.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IMUC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -32.2  Med: -5.60 Max: 102.7
Current: -10.6
-32.2
102.7
EPS Growth (3Y)(%) -8.70
IMUC's EPS Growth (3Y)(%) is ranked lower than
51% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. IMUC: -8.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IMUC' s 10-Year EPS Growth (3Y)(%) Range
Min: -28.1  Med: -4.40 Max: 81.7
Current: -8.7
-28.1
81.7
» IMUC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

IMUC Guru Trades in Q3 2014

Paul Tudor Jones 50,124 sh (+23.55%)
» More
Q4 2014

IMUC Guru Trades in Q4 2014

Jim Simons 104,316 sh (New)
Paul Tudor Jones Sold Out
» More
Q1 2015

IMUC Guru Trades in Q1 2015

Jim Simons 446,000 sh (+327.55%)
» More
Q2 2015

IMUC Guru Trades in Q2 2015

Jim Simons 1,702,692 sh (+281.77%)
» More
» Details

Insider Trades

Latest Guru Trades with IMUC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.27
IMUC's P/B is ranked higher than
91% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. IMUC: 1.27 )
Ranked among companies with meaningful P/B only.
IMUC' s 10-Year P/B Range
Min: 1.18  Med: 8.07 Max: 17.42
Current: 1.27
1.18
17.42
Current Ratio 39.19
IMUC's Current Ratio is ranked higher than
97% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. IMUC: 39.19 )
Ranked among companies with meaningful Current Ratio only.
IMUC' s 10-Year Current Ratio Range
Min: 2.64  Med: 19.34 Max: 76.13
Current: 39.19
2.64
76.13
Quick Ratio 39.19
IMUC's Quick Ratio is ranked higher than
97% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. IMUC: 39.19 )
Ranked among companies with meaningful Quick Ratio only.
IMUC' s 10-Year Quick Ratio Range
Min: 2.64  Med: 19.34 Max: 76.13
Current: 39.19
2.64
76.13

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.37
IMUC's Price/Net Cash is ranked higher than
95% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 7.71 vs. IMUC: 1.37 )
Ranked among companies with meaningful Price/Net Cash only.
IMUC' s 10-Year Price/Net Cash Range
Min: 1  Med: 4.73 Max: 93.75
Current: 1.37
1
93.75
Price/Net Current Asset Value 1.28
IMUC's Price/Net Current Asset Value is ranked higher than
95% of the 537 Companies
in the Global Biotechnology industry.

( Industry Median: 6.85 vs. IMUC: 1.28 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IMUC' s 10-Year Price/Net Current Asset Value Range
Min: 0.96  Med: 4.45 Max: 77
Current: 1.28
0.96
77
Price/Tangible Book 1.24
IMUC's Price/Tangible Book is ranked higher than
92% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. IMUC: 1.24 )
Ranked among companies with meaningful Price/Tangible Book only.
IMUC' s 10-Year Price/Tangible Book Range
Min: 0.96  Med: 4.39 Max: 77
Current: 1.24
0.96
77
Earnings Yield (Greenblatt) (%) -145.23
IMUC's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. IMUC: -145.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IMUC' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -237.32  Med: 0.00 Max: 0
Current: -145.23
-237.32
0

Analyst Estimate

Dec15 Dec16 Dec17
EPS($) -0.13 -0.24 -0.26
EPS without NRI($) -0.13 -0.24 -0.26

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:KOL.Germany,
ImmunoCellular Therapeutics Ltd was incorporated with the Secretary of State of Delaware on March 20, 1987 under the name Redwing Capital Corp. On November 2, 2006, it amended its Certificate of InCorporation to change its name to ImmunoCellular Therapeutics, Ltd. The Company is a clinical-stage biotechnology company developing immune-based therapies for the treatment of cancers, such as brain and ovarian. Immunotherapy is an approach to treating cancer in which a patient's own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company's product candidate portfolio includes; ICT-107, ICT-121, and ICT-140. The ICT-107 is a DC-based vaccine targeting CSCs and cancer antigens that targets six different tumor-associated antigens that are found on patients' tumor cells; at least four of the six antigens are highly expressed on CSCs. The therapeutic vaccine is used subsequent to conventional therapy or concomitantly with chemotherapy in patients with newly diagnosed GBM. On February 2014, ICT-107 was granted Orphan Drug status by the European Medicines Agency. The ICT-121 is a DC-based vaccine targeting CD133+ CSCs marker that is overexpressed in a wide variety of solid tumors, including ovarian, pancreatic, and breast cancers. The ICT-140 is a DC-based vaccine targeting CSCs and cancer antigens and targets seven different ovarian cancer antigens. Ovarian cancer usually spreads via local shedding into the peritoneal cavity followed by implantation on the peritoneum and via local invasion of bowel and bladder. The Company faces competition from the companies that have significantly more experience in undertaking preclinical testing and human clinical trials with new or improved therapeutic products and obtaining regulatory approvals of such products. The United States and other developed countries regulate the preclinical and clinical testing, manufacturing, labeling, storage, record-keeping, advertising, promotion, export, marketing and distribution of drugs and biologic products. The United States Food and Drug Administration, under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal statutes and regulations, regulate pharmaceutical and biologic products.
» More Articles for IMUC

Headlines

Articles On GuruFocus.com
creiter note on IMUC Jan 03 2010 

More From Other Websites
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Other Events, Financial Statements and... Aug 26 2015
ImmunoCellular Therapeutics Issues Letter to Shareholders, Highlighting Progress on Advancing... Aug 21 2015
ImmunoCellular Therapeutics Issues Letter to Shareholders, Highlighting Progress on Advancing... Aug 21 2015
IMMUNOCELLULAR THERAPEUTICS, LTD. Financials Aug 19 2015
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Aug 17 2015
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Other Events, Financial Statements and... Aug 14 2015
ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment (SPA) for... Aug 13 2015
ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment (SPA) for... Aug 13 2015
10-Q for ImmunoCellular Therapeutics Ltd. Aug 09 2015
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 10-Q, Quarterly Report Aug 07 2015
Edited Transcript of IMUC earnings conference call or presentation 6-Aug-15 9:00pm GMT Aug 07 2015
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 06 2015
ImmunoCellular Therapeutics Ltd Earnings Call scheduled for 5:00 pm ET today Aug 06 2015
ImmunoCellular Therapeutics Announces Second Quarter 2015 Financial Results Aug 06 2015
ImmunoCellular Therapeutics Announces Second Quarter 2015 Financial Results Aug 06 2015
Q2 2015 ImmunoCellular Therapeutics Ltd Earnings Release - After Market Close Aug 06 2015
ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 Jul 23 2015
ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 Jul 23 2015
ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3... Jul 06 2015
ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3... Jul 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK